Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without ...

LOS ANGELES, June 25 (Reuters) - Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S ...

Wegovy received U.S. Food and Drug Administration (FDA) approval and was launched in June 2021, and Zepbound entered the market in December 2023 as a new contender.

Hims teamed up with Novo Nordisk A/S in April to offer its rival drug Wegovy at a discounted price to patients who use its platform. The telehealth company — and its investors — had been ...

If HS-20094 becomes nearly as successful as Zepbound, the $80 million Regeneron paid -- and the $1.93 billion in milestones -- would represent quite the bargain. However, it is too early to celebrate.

People taking Zepbound lost more body weight. Those on Zepbound lost 20.2% of their body weight (about 50 pounds on average), while participants on Wegovy lost 13.7% (about 33 pounds).

Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.

The main result – reported earlier – was an overall weight reduction of 20.2% with Zepbound at 72 weeks, compared to 13.7% with Wegovy.

Zepbound joins the GLP-1 ranks for weight loss with Wegovy and Saxenda. Tirzepatide is the main ingredient in Zepbound, approved label for weight management, and Mounjaro, the brand name approved ...

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

Shares of Scholar Rock jumped 16% in premarket trading. Scholar's drug, apitegromab, when combined with Zepbound preserved an additional 1.9 kilograms of lean mass when compared with Zepbound alone.